Medical anticancer treatment of lung cancer associated with comorbidities: A review

Sculier, Jean-Paul; Botta, Ilaria; Bucalau, Ana-Maria; Compagnie, M J; Eskenazi, Allen E.; Fischler, Rinaldo; Gorham, Julie; Mans, Laura; Rozen, Lionel; Speybrouck, Sabrina; Wang, X; Meert, Anne-Pascale; Berghmans, Thierry

doi:10.1016/j.lungcan.2015.01.007

Cited by 10 publications

(7 citation statements)

References 77 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors were optimally clustered with anxiety and depression. The results obtained in this study are validated by other studies that have indicated that patients with anxiety and osteoporosis easily encounter more complications than those with several other disease groups [29][30][31]. The results of this study indicate that young patients with lung cancer and osteoporosis are also at a high risk for the onset of anxiety.…”

Section: Discussionsupporting

confidence: 85%

“…The surgical rate and radiotherapy rate for lung cancer showed a general downward trend, while the chemotherapy rate experienced a significantly increasing trend [30]. Although the five-year relative survival rate has increased over the years, it has remained very low for the last 20 years [31]. Therefore, this study, which used a nationwide database from 2001 to 2007, can still provide useful findings for clinicians.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm

Fang

Liu

2021

Medicina

View full text Add to dashboard Cite

Background and Objectives: Identifying risk factors associated with psychiatrist-confirmed anxiety and depression among young lung cancer patients is very difficult because the incidence and prevalence rates are obviously lower than in middle-aged or elderly patients. Due to the nature of these rare events, logistic regression may not successfully identify risk factors. Therefore, this study aimed to propose a novel algorithm for solving this problem. Materials and Methods: A total of 1022 young lung cancer patients (aged 20–39 years) were selected from the National Health Insurance Research Database in Taiwan. A novel algorithm that incorporated a k-means clustering method with v-fold cross-validation into multiple correspondence analyses was proposed to optimally determine the risk factors associated with the depression and anxiety of young lung cancer patients. Results: Five clusters were optimally determined by the novel algorithm proposed in this study. Conclusions: The novel Multiple Correspondence Analysis–k-means (MCA–k-means) clustering algorithm in this study successfully identified risk factors associated with anxiety and depression, which are considered rare events in young patients with lung cancer. The clinical implications of this study suggest that psychiatrists need to be involved at the early stage of initial diagnose with lung cancer for young patients and provide adequate prescriptions of antipsychotic medications for young patients with lung cancer.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 82%

Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm

Fang

Liu

2021

Medicina

View full text Add to dashboard Cite

show abstract

“…As in other chronic inflammatory syndromes, many cancer patients suffer chronic pain, depression, behavioural disorders and fatigue, and some cancer treatments exacerbate these comorbidities 92 . Elevated Trp catabolism in the TME might contribute to these neurologic comorbidities, as some Trp catabolites are neuroactive (Fig.…”

Section: [H2] Elevated Trp Catabolism and Cancer Comorbiditiesmentioning

confidence: 99%

Immune control by amino acid catabolism during tumorigenesis and therapy

et al. 2019

View full text Add to dashboard Cite

Immune checkpoints arise from physiologic changes during tumourigenesis that re-programme inflammatory, immunologic and metabolic processes in malignant lesions and local lymphoid tissues, which constitute the immunologic tumour microenvironment (TME). Improving clinical responses to immune checkpoint blockade will require deeper understanding of factors that impact local immune balance in the TME. Elevated catabolism of the amino acids tryptophan (Trp) and arginine (Arg) are common TME hallmarks at clinical presentation of cancer. Cells catabolising Trp and Arg suppress effector T cells and stabilize regulatory T cells (Tregs) to suppress immunity in chronic inflammatory diseases of clinical significance, including cancers.Processes that induce Trp and Arg catabolism in the TME remain incompletely defined.Indoleamine 2,3 dioxygenase (IDO) and arginase (ARG1), which catabolise Trp and Arg respectively, respond to inflammatory cues including interferons (IFNs) and TGFβ cytokines.Dying cells generate inflammatory signals including DNA, which is sensed to stimulate the production of type I IFNs via the Stimulator of Interferon Genes (STING) adaptor. Thus, dying cells help establish local conditions that suppress anti-tumour immunity to promote tumourigenesis. Here we review evidence that Trp and Arg catabolism contributes to inflammatory processes that promote tumourigenesis, impede immune responses to therapy and might promote neurologic comorbidities associated with cancer.

show abstract

“…Specific data concerning dose adaptation of systemic therapies (chemotherapies and targeted therapies) according to comorbidities are seldom seen in the literature, except with regards renal and hepatic failure. A review of medical cancer treatment of lung cancer associated with comorbidities has recently been published [105], emphasising the need for a better appraisal of the impact of comorbidities.…”

Section: Impact Of Comorbidities On the Use Of Systemic Treatmentmentioning

confidence: 99%

Comorbidities in the management of patients with lung cancer

Leduc

Antoni²,

Charloux³

et al. 2017

Eur Respir J

View full text Add to dashboard Cite

Lung cancer represents a major public health issue worldwide. Unfortunately, more than half of them are diagnosed at an advanced stage. Moreover, even if diagnosed early, diagnosis procedures and treatment can be difficult due to the frequent comorbidities observed in these patients. Some of these comorbidities have a common major risk factor, smoking, whereas others are unrelated to smoking but frequently observed in the general population. These comorbidities must be carefully assessed before any diagnostic and/or therapeutic decisions are made regarding the lung cancer. For example, in a patient with severe emphysema or with diffuse lung fibrosis, transthoracic needle biopsy can be contraindicated, meaning that in some instances a precise diagnosis cannot be obtained; in a patient with chronic obstructive pulmonary disease, surgery may be impossible or should be preceded by intensive rehabilitation; patients with interstitial lung disease are at risk of radiation pneumonitis and should not receive drugs which can worsen the respiratory insufficiency. Patients who belong to what are called "special populations", elderly or HIV infected, should be treated specifically, especially regarding systemic treatment. Last but not least, psychosocial factors are of great importance and can vary from one country to another according to health insurance coverage.

show abstract

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Cited by 10 publications

References 77 publications

Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm

Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm

Immune control by amino acid catabolism during tumorigenesis and therapy

Comorbidities in the management of patients with lung cancer

Contact Info

Product

Resources

About